Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SNDX Syndax Pharmaceuticals

Closed 04-09 16:00:00 EDT

24.76

+0.20

+0.81%

盘后24.76

+0.000.00%

19:06 EDT

High24.94	Low24.28	Vol702.73K
Open24.40	D1 Closing24.56	Amplitude2.67%
Mkt Cap2.18B	Tradable Cap1.85B	Total Shares88.20M
T/O17.35M	T/O Rate0.94%	Tradable Shares74.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals","latestPrice":24.76,"timestamp":1775764800000,"preClose":24.56,"halted":0,"volume":702729,"hourTrading":{"tag":"盘后","latestPrice":24.76,"preClose":24.76,"latestTime":"19:06 EDT","volume":38323,"amount":948878.46,"timestamp":1775775977807,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.008143322475570149,"floatShares":74690800,"shares":88200596,"eps":-3.294891,"marketStatus":"Closed","change":0.2,"latestTime":"04-09 16:00:00 EDT","open":24.4,"high":24.935,"low":24.28,"amount":17349163.28883,"amplitude":0.026669,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.294891,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775808000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1456981200000,"exchange":"NASDAQ","adjPreClose":24.56,"preHourTrading":{"tag":"盘前","latestPrice":24.39,"preClose":24.56,"latestTime":"09:29 EDT","volume":436,"amount":10668.319192,"timestamp":1775741399999,"change":-0.17,"changeRate":-0.006922,"amplitude":0.013029},"postHourTrading":{"tag":"盘后","latestPrice":24.76,"preClose":24.76,"latestTime":"19:06 EDT","volume":38323,"amount":948878.46,"timestamp":1775775977807,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.38876,"impliedVol":0.632,"impliedVolPercentile":0.364},"requestUrl":"/m/hq/s/SNDX/tweets","defaultTab":"tweets","newsList":[{"id":"2625608557","title":"Your Stock Just Doubled. What to Do Now. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2625608557","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625608557?lang=en_us&edition=fundamental","pubTime":"2026-04-07 00:47","pubTimestamp":1775494020,"startTime":"0","endTime":"0","summary":"If you own Sandisk, Western Digital, or Micron stock, congrats.They -- and any number of other red-hot AI momentum plays -- have more than doubled in the past year. Now, for a dose of reality: Companies that enjoy a huge pop end up limping along for years.Sanhueza and deGraaf looked at what happens after a stock doubles in price over a short period of time -- anywhere from 10 to 252 trading days. They studied \"bubble events\" for companies in the Russell 3000 index, from 1984 to this year.\"Across large-cap, small-cap, and broad-market universes, stocks that double rapidly tend to underperform over the subsequent 36 months,\" they wrote.Though forward returns for large-caps after a doubling were \"generally weak,\" they researchers wrote, smaller-caps showed \"more abrupt and severe declines.\". In the S&P 500 index, 24 companies have shot up more than 100% in the past 12 months. Many, but not all, are in the tech sector. Chip and semiconductor equipment companies Intel, AMD, Applied Material","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDCX","NEM","INTC","LU1815336760.USD","CIEN","LU1069347547.HKD","LU1235294995.USD","KLAC","LU0054578231.USD","04336","LU0476273544.USD","BK4585","AMAT","LU0444973449.USD","LITE","LU0081259029.USD","LU1035773651.USD","SNDX","LU1823568750.SGD","MU","APA","SNXX","LU1046421795.USD","WDC","GB00BDT5M118.USD","LU0006061336.USD","LU0444971666.USD","LU1642822529.SGD","04335","BK4170","AMD","CAT","LU0963586101.USD","BK4588","LU0957808578.USD","BK4512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624065661","title":"Syndax grants inducement stock options for up to 228,500 shares to new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2624065661","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624065661?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:01","pubTimestamp":1775246475,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals granted inducement stock options covering up to 228,500 common shares to eight new employees under its 2023 Inducement Plan.Options vest over four years, with 25% vesting on one-year anniversary of vesting start date.Remaining options vest in equal monthly installments of 1/48 over the next 36 months, subject to continued service.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDLg6rjK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014021.USD","IE00BKPKM429.USD","NDAQ","IE00B64PRP62.GBP","SG9999014039.USD","IE00BN0W2T93.GBP","SNDX","SG9999014013.SGD","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD","BK4585","BK4112","BK4139","IE00BN0W2W23.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4588","IE00BN0W2V16.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624579802","title":"Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After An 84% One Year Share Price Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2624579802","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624579802?lang=en_us&edition=fundamental","pubTime":"2026-04-02 14:30","pubTimestamp":1775111446,"startTime":"0","endTime":"0","summary":"If you are wondering whether Syndax Pharmaceuticals' current share price reflects its true worth, this article walks through the key valuation checks that can help you frame that question clearly.\nThe stock recently closed at US$23.88, after a 7.9% gain over the past month, a 12.1% return year to date, and 84.1% over the last year. These moves may have changed how the market views both its potential and its risks.\nRecent coverage has focused on Syndax Pharmaceuticals in the context of its...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/is-it-time-to-reassess-syndax-pharmaceuticals-sndx-after-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/is-it-time-to-reassess-syndax-pharmaceuticals-sndx-after-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SNDX","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624543021","title":"Syndax Pharmaceuticals Is Maintained at Buy by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2624543021","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624543021?lang=en_us&edition=fundamental","pubTime":"2026-04-02 02:00","pubTimestamp":1775066400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2026 14:00 ET (18:00 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624863543","title":"Micron, Other Memory Stocks Surge. Markets Are Back in Risk-On Mode. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2624863543","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624863543?lang=en_us&edition=fundamental","pubTime":"2026-04-02 01:13","pubTimestamp":1775063580,"startTime":"0","endTime":"0","summary":"Micron Technology and its memory and data-storage peers led the market higher on Wednesday. Investors are rotating back to momentum stocks after a brutal March.Micron shares, which are leading the S&P 500, rose by 11%. Flash-memory rival Sandisk is close behind with a 10% gain. Data-storage duo Western Digital and Seagate Technology jumped by 10% and 7.6%, respectively.The sharp moves signaled a return to large-cap momentum stocks as the second quarter got under way. The Invesco S&P 500 Pure Growth exchange-traded fund, which currently counts Sandisk and Micron among its top 10 holdings, rose by 3.2% Wednesday. That was a reversal from last month, when investors sold off tech stocks and picked up energy names in response to the Iran war.Micron and Sandisk, plus Western Digital and Seagate, perfectly encapsulate momentum. All four were among the largest risers in the S&P 500 last year, jumping by triple digits as artificial intelligence boosted demand for memory chips and data storage.T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GB00BDT5M118.USD","IE00B5949003.HKD","LU0157215616.USD","LU0274383776.USD","BK4579","BK4533","BK4605","LU0642271901.SGD","BK4566","LU0719512351.SGD","LU0889565833.HKD","BK4141","LU1316542783.SGD","LU1670628061.USD","BK4512","LU0154236417.USD","LU2089985449.USD","STX","WDC","BK4585","IE00B19Z3581.USD","LU1670627923.USD","LU0792757196.USD","LU0081259029.USD","LU2286300806.USD","LU1323610961.USD","LU2458330243.SGD","IE00B894F039.SGD","IE0009356076.USD","LU0127658192.USD","LU1267930813.SGD","LU2458330169.SGD","SNDX","LU2250418816.HKD","LU2360106780.USD","BK4554","LU0889566641.SGD","MU","LU2931357623.SGD","BK4170","BK4543","MUU","BK4527","IE00B19Z9P08.USD","BK4575","LU2054465674.USD","LU1852331112.SGD","LU2048586759.USD","LU2543165471.USD","IE00B7SZLL34.SGD","BK4553","MULL","BK4588","MUD","LU2211815571.USD","LU0109392836.USD","LU0082616367.USD","IE00B19Z3B42.SGD","LU0203347892.USD","LU1366333091.USD","LU1803068979.SGD","IE00B19Z9Z06.USD","LU0203345920.USD","IE0002270589.USD","BK4532","LU0056508442.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623585338","title":"Syndax price target raised to $34 from $28 at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2623585338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623585338?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:13","pubTimestamp":1774955618,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Corinne Johnson raised the firm’s price target on Syndax (SNDX) to $34 from $28 and keeps a Buy rating on the shares. Ahead o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-price-target-raised-to-34-from-28-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-price-target-raised-to-34-from-28-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0048573561.USD","LU2237443382.USD","LU0106831901.USD","BK4139","LU1868836757.USD","IE00B19Z3B42.SGD","LU2750360641.GBP","LU0251131958.USD","LU1894683348.USD","BK4550","IE00BSNM7G36.USD","BK4585","IE0004091025.USD","IE0004086264.USD","BK4516","LU2237443895.HKD","LU2237443978.SGD","IE0034235188.USD","BK4533","LU2237443622.USD","LU0742534661.SGD","LU2237443465.HKD","BK4127","LU2237443549.SGD","IE00BFXG1179.USD","IE00B19Z3581.USD","BK4504","BK4552","LU0345770308.USD","LU2237438978.USD","LU1668664300.SGD","SNDX","LU1868836591.USD","LU1791807156.HKD","LU0345770993.USD","LU1868836914.USD","LU2471134952.CNY","LU2471134523.USD","LU0061475181.USD","LU0096364046.USD","IE0002270589.USD","LU0251142724.SGD","BK4588","LU2265009873.SGD","LU2471134796.USD","LU2471134879.HKD","GSX","LU1868837300.USD","LU1868837136.USD","LU1894683264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345619","title":"Jefferies Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345619","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345619?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:38","pubTimestamp":1774877928,"startTime":"0","endTime":"0","summary":"Jefferies analyst maintained a Buy rating on Syndax Pharmaceuticals today and set a price target of $40.00. Currently, the analyst consensus on Syn...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-keeps-their-buy-rating-on-syndax-pharmaceuticals-sndx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-keeps-their-buy-rating-on-syndax-pharmaceuticals-sndx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623439923","title":"Mizuho Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623439923","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623439923?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:16","pubTimestamp":1774876586,"startTime":"0","endTime":"0","summary":"In a report released today, from Mizuho Securities maintained a Buy rating on Syndax Pharmaceuticals, with a price target of $43.00. The word on Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-syndax-pharmaceuticals-sndx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-syndax-pharmaceuticals-sndx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619170549","title":"Assessing Whether Syndax Pharmaceuticals (SNDX) Still Looks Undervalued After Its Recent Strong Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2619170549","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619170549?lang=en_us&edition=fundamental","pubTime":"2026-03-15 14:22","pubTimestamp":1773555734,"startTime":"0","endTime":"0","summary":"What Syndax Pharmaceuticals (SNDX) Investors Are Watching Right Now\nSyndax Pharmaceuticals (SNDX) has drawn fresh attention after recent trading, with the stock closing at US$23.50 and showing double digit total returns over the past year and the past 3 months.\nSee our latest analysis for Syndax Pharmaceuticals.\nThat latest 1 day share price decline of 2.04% comes after a strong run, with a 30 day share price return of 14.75% and 1 year total shareholder return of 81.47%. This suggests...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/assessing-whether-syndax-pharmaceuticals-sndx-still-looks-un","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/assessing-whether-syndax-pharmaceuticals-sndx-still-looks-un","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SNDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618655673","title":"Syndax Pharmaceuticals Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2618655673","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618655673?lang=en_us&edition=fundamental","pubTime":"2026-03-10 00:52","pubTimestamp":1773075120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 12:52 ET (16:52 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618064801","title":"U.S. RESEARCH ROUNDUP-Dow, Oracle, Shopify","url":"https://stock-news.laohu8.com/highlight/detail?id=2618064801","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618064801?lang=en_us&edition=fundamental","pubTime":"2026-03-09 15:34","pubTimestamp":1773041646,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Dow, Oracle, ShopifyMarch 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Monday, including Dow, Oracle ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4N3ZX0MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRWG","T","AVTR","GCO","CHRD","ORCS","GWRE","CERT","BK4532","ORCX","DAWN","SHOP","LDOS","DVN","SHPU","CAT","SNDX","USAC","ANAB","EVRG","HTO","ADBG","IE00BYQQ9H92.USD","CRWU","EMN","HRI","LU2083900584.USD","AEYE","CWVX","ORCL","SHPD","CORD","AKTS","CRWV","CTRA","OVV","DOW","APA","ORCU","APC","DE","MWH","BROS","INSW","FANG","ADBE","AVA","LU1261432733.SGD","EBS","FTRE"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618611377","title":"Syndax Pharmaceuticals Inc : JP Morgan Raises Target Price to $45 From $33","url":"https://stock-news.laohu8.com/highlight/detail?id=2618611377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618611377?lang=en_us&edition=fundamental","pubTime":"2026-03-09 12:22","pubTimestamp":1773030135,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX00U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617665522","title":"Syndax Pharmaceuticals’ Earnings Call Highlights Growth Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2617665522","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617665522?lang=en_us&edition=fundamental","pubTime":"2026-03-08 08:21","pubTimestamp":1772929282,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc. (($SNDX)) has held its Q4 earnings call. Read on for the main highlights of the call. Syndax Pharmaceuticals’ latest ea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/syndax-pharmaceuticals-earnings-call-highlights-growth-push?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/syndax-pharmaceuticals-earnings-call-highlights-growth-push?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617696925","title":"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617696925","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617696925?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:01","pubTimestamp":1772658060,"startTime":"0","endTime":"0","summary":"NEW YORK, March  04, 2026  (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249711/0/en/Syndax-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIW.SI","QLD","USAW.SI","PSQ","QQQE","SQQQ","QQQJ","QYLD","QQQY","NQmain","QID","SNDX","GPIQ","TSYW.SI","USJW.SI","TQQQ",".IXIC","QYLG","MNQmain","JEPQ","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2616363919","title":"Syndax Pharmaceuticals Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2616363919","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616363919?lang=en_us&edition=fundamental","pubTime":"2026-03-03 03:28","pubTimestamp":1772479680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 14:28 ET (19:28 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616055339","title":"Syndax price target raised to $57 from $51 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2616055339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616055339?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:59","pubTimestamp":1772452774,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Syndax (SNDX) to $57 from $51 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-price-target-raised-to-57-from-51-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-price-target-raised-to-57-from-51-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616805997","title":"Syndax’s Third FDA Win Accelerates Shift To Multi Product Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2616805997","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616805997?lang=en_us&edition=fundamental","pubTime":"2026-03-02 09:22","pubTimestamp":1772414563,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals secured its third FDA approval within a year, following the launches of Revuforj and Niktimvo.\nThe company is rapidly shifting into a commercial-stage model with revenues now coming from multiple newly approved therapies.\nPivotal clinical trials are in progress that could support label expansions and additional indications.\n\nSyndax Pharmaceuticals, NasdaqGS:SNDX, is moving from a pure R&D story to an active commercial player, supported by three FDA approved therapies...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndaxs-third-fda-win-accelerates-shift-to-multi-product-rev","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndaxs-third-fda-win-accelerates-shift-to-multi-product-rev","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162300076","title":"Stock Track | Syndax Pharmaceuticals Soars 5.04% Intraday on Positive Analyst Coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=1162300076","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162300076?lang=en_us&edition=fundamental","pubTime":"2026-02-28 04:58","pubTimestamp":1772225908,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals' stock surged 5.04% during intraday trading on Friday, reflecting strong investor interest in the pharmaceutical company.The price movement appears to be driven by positive...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614583032","title":"H.C. Wainwright Remains a Buy on Syndax Pharmaceuticals (SNDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614583032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614583032?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:35","pubTimestamp":1772192158,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Syndax Pharmaceuticals today and set a price target of $40.00. According to ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-syndax-pharmaceuticals-sndx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-syndax-pharmaceuticals-sndx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614719520","title":"Syndax reports Q4 EPS (78c), consensus (58c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614719520","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614719520?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:39","pubTimestamp":1772141969,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $68.73M, consensus $64.75M. As of December 31, 2025, Syndax (SNDX) had cash, cash equivalents, and short-term investments of $39...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-reports-q4-eps-78c-consensus-58c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-reports-q4-eps-78c-consensus-58c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNDX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":0.0285},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.1482},{"period":"6month","weight":0.5293},{"period":"1year","weight":1.3258},{"period":"ytd","weight":0.169}],"compareEarnings":[{"period":"1week","weight":0.0317},{"period":"1month","weight":-0.0033},{"period":"3month","weight":-0.0196},{"period":"6month","weight":0.0352},{"period":"1year","weight":0.3616},{"period":"ytd","weight":-0.0087}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.039298},{"month":2,"riseRate":0.7,"avgChangeRate":0.080379},{"month":3,"riseRate":0.6,"avgChangeRate":0.053723},{"month":4,"riseRate":0.454545,"avgChangeRate":0.017969},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019495},{"month":6,"riseRate":0.5,"avgChangeRate":-0.003538},{"month":7,"riseRate":0.6,"avgChangeRate":0.016261},{"month":8,"riseRate":0.6,"avgChangeRate":0.106119},{"month":9,"riseRate":0.5,"avgChangeRate":-0.031411},{"month":10,"riseRate":0.2,"avgChangeRate":-0.077781},{"month":11,"riseRate":0.6,"avgChangeRate":0.04592},{"month":12,"riseRate":0.5,"avgChangeRate":0.035938}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Syndax Pharmaceuticals,SNDX,Syndax Pharmaceuticals股票,Syndax Pharmaceuticals股票老虎,Syndax Pharmaceuticals股票老虎国际,Syndax Pharmaceuticals行情,Syndax Pharmaceuticals股票行情,Syndax Pharmaceuticals股价,Syndax Pharmaceuticals股市,Syndax Pharmaceuticals股票价格,Syndax Pharmaceuticals股票交易,Syndax Pharmaceuticals股票购买,Syndax Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction